摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide | 67299-16-5

中文名称
——
中文别名
——
英文名称
2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide
英文别名
2,3-Dihydro-N-methylbenzisothiazol;2,3-dihydro-1,1-dioxo-2-methyl-1,2-benzisothiazole;2-methyl-2,3-dihydro-benz[d]isothiazole-1,1-dioxide;2-Methyl-2,3-dihydro-benz[d]isothiazol-1,1-dioxid;2,3-Dihydro-2-methyl-1,2-benzisothiazole-1,1-dione;2-methyl-3H-1,2-benzothiazole 1,1-dioxide
2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide化学式
CAS
67299-16-5
化学式
C8H9NO2S
mdl
——
分子量
183.231
InChiKey
LHGGZFWXQZSSEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    124-126 °C
  • 沸点:
    318.5±45.0 °C(Predicted)
  • 密度:
    1.345±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    45.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide硫酸lead dioxide 作用下, 生成 2-methyl-3-(N'-phenyl-hydrazino)-2,3-dihydro-benz[d]isothiazole-1,1-dioxide
    参考文献:
    名称:
    Etude sur le pouvoir氧化剂氯胺
    摘要:
    DOI:
    10.1002/hlca.19300130414
  • 作为产物:
    描述:
    N,2-dimethylbenzenesulfonamidedisodium hydrogenphosphate 、 (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate 、 三氯异氰尿酸 作用下, 以 二氯甲烷乙腈 为溶剂, 反应 19.0h, 生成 2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide
    参考文献:
    名称:
    Visible-Light-Promoted Remote C(sp3)–H Amidation and Chlorination
    摘要:
    A visible-light-promoted C(sp(3))-H amidation and chlorination of N-chlorosulfonamides (NCSs) is reported. This remote C(sp(3))-H functionalization can be achieved in weak basic solution at room temperature with as little as 0.1 mol % of a photocatalyst. A variety of nitrogen-containing heterocycles (up to 94% yield) and chlorides (up to 93% yield) are prepared from NCSs. Late-stage C(sp3)H functionalization of complex and biologically important (-)-cis-myrtanylamine and (+)-dehydroabietylamine derivatives can also be achieved with excellent yields and regioselectivity.
    DOI:
    10.1021/acs.orglett.5b00582
点击查看最新优质反应信息

文献信息

  • Investigation of the Mechanism of C(sp<sup>3</sup>)−H Bond Cleavage in Pd(0)-Catalyzed Intramolecular Alkane Arylation Adjacent to Amides and Sulfonamides
    作者:Sophie Rousseaux、Serge I. Gorelsky、Benjamin K. W. Chung、Keith Fagnou
    DOI:10.1021/ja103081n
    日期:2010.8.11
    reactivity of C(sp(3))-H bonds adjacent to a nitrogen atom can be tuned to allow intramolecular alkane arylation under Pd(0) catalysis. Diminishing the Lewis basicity of the nitrogen lone pair is crucial for this catalytic activity. A range of N-methylamides and sulfonamides react exclusively at primary C(sp(3))-H bonds to afford the products of alkane arylation in good yields. The isolation of a Pd(II) reaction
    可以调整与氮原子相邻的 C(sp(3))-H 键的反应性,以允许在 Pd(0) 催化下进行分子内烷烃芳基化。降低氮孤对的路易斯碱度对于这种催化活性至关重要。一系列 N-甲基酰胺和磺酰胺仅在初级 C(sp(3))-H 键上反应,以高产率提供烷烃芳基化产物。Pd(II) 反应中间体的分离使得能够评估反应机理,重点是碱在 C(sp(3))-H 键断裂步骤中的作用。这些化学计量研究的结果,连同动力学同位素效应实验,为协调的属化-去质子化 (CMD) 过渡态提供了罕见的实验支持,此前已在烷烃 C(sp(3))-H 芳基化中提出了这种过渡态。而且,DFT 计算揭示了新戊酸盐添加剂作为磷化氢从 Pd(II) 中间体解离的促进剂的额外作用,使 CMD 过渡态成为可能。最后,进行了动力学研究,揭示了反应速率表达及其与新戊酸盐浓度的关系。
  • [EN] DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS<br/>[FR] DÉRIVÉS DE DIBENZOTHIOPHÈNE EN TANT QU'INHIBITEURS D'ADN-PK
    申请人:KUDOS PHARM LTD
    公开号:WO2010136778A1
    公开(公告)日:2010-12-02
    Compound formula I: wherein: X1 and X2 may be either (a) C and O, (b) N and N, or (c) C and NH, where the dotted bonds represents a double bond in the appropriate location; R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, or an optionally substituted C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; RN1 is selected from hydrogen and an optionally substituted C1-4 alkyl group; RC1 is selected from an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, or an optionally substituted C5-20 aryl group; or RN1 and RC1 may together form an optionally substituted C2-4 alkylene group.
    化合物公式I:其中:X1和X2可以是(a)C和O,(b)N和N,或(c)C和NH,其中点线代表适当位置的双键;R1和R2分别从氢,可选择的取代的C1-7烷基基团,可选择的取代的C3-20杂环基团,或可选择的取代的C5-20芳基基团中独立选择,或者可以与它们附着的氮原子一起形成具有4至8个环原子的可选择取代的杂环环;RN1从氢和可选择的取代的C1-4烷基基团中选择;RC1从可选择的取代的C1-7烷基基团,可选择的取代的C3-20杂环基团,或可选择的取代的C5-20芳基基团中选择;或RN1和RC1可以一起形成一个可选择取代的C2-4烷基烃基团。
  • [EN] DNA PK INHIBITORS<br/>[FR] INHIBITEURS DE L'ADN-PK
    申请人:KUDOS PHARM LTD
    公开号:WO2009010761A1
    公开(公告)日:2009-01-22
    A compound of formula (I): wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocydyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X is CH or N; n is 1 or 2; RC1 and RC2 are independently selected from H and methyl; when X is N, Rx is selected from the group consisting of H, and optionally substituted C1-7 alkyl, C3-20 heterocydyl, C5-20 aryl, acyl, ester, amido and sulfonyl; and when X is CH, Rx is selected from the group consisting of H, and optionally substituted C1-7 alkyl, C3-2O heterocyclyl, C5-20 aryl, acyl, ester, amido, sulfonyl, amino and ether. The compounds according to formula (I) are DNA-PK inhibitors, useful in the treatment of tumours and retroviral mediated diseases.
    公式(I)的化合物:其中:R1和R2独立地选自氢、一个可选地取代的C1-7烷基团、C3-20杂环烷基团或C5-20芳基团,或者可以共同形成,连同它们所连接的氮原子,一个从4到8个环原子组成的可选地取代的杂环;X是CH或N;n是1或2;RC1和RC2独立地选自H和甲基;当X是N时,Rx选自由H、和可选地取代的C1-7烷基、C3-20杂环烷基、C5-20芳基、酰基、酯、酰胺和磺酰基组成的组;当X是CH时,Rx选自由H、和可选地取代的C1-7烷基、C3-20杂环烷基、C5-20芳基、酰基、酯、酰胺、磺酰基、基和醚组成的组。根据公式(I)的化合物是DNA-PK抑制剂,在治疗肿瘤和逆转录病毒介导的疾病中有效。
  • [EN] PYRROLO [2, 3-B] PYRIDIN DERIVATIVES AS IKK2 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRIDINE COMME INHIBITEURS DE L'IKK2
    申请人:GLAXO GROUP LTD
    公开号:WO2009112475A1
    公开(公告)日:2009-09-17
    The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I):and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    这项发明涉及某些新颖的化合物。具体而言,该发明涉及符合以下式(I)的化合物及其盐。该发明的化合物是激酶活性抑制剂,特别是IKK2活性的抑制剂
  • [EN] HETEREOARYL NITRILE DERIVATIVES<br/>[FR] DERIVES D'HETEREOARYLE NITRILE
    申请人:NOVARTIS AG
    公开号:WO2004020441A1
    公开(公告)日:2004-03-11
    The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    该发明提供了式(I)的化合物或其药用可接受的盐或酯,其中符号的含义如定义,这些化合物是卡特普辛K的抑制剂,并在药学上用于治疗卡特普辛K参与的疾病和医疗状况,例如各种疾病,包括炎症、类风湿关节炎、骨关节炎、骨质疏松症和肿瘤。
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 齐帕西酮-d8 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲酸,4-(6-辛基-2-苯并噻唑基)- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[2-[4-(二甲氨基)苯基]乙烯基]-3-乙基-6-甲基-,碘化 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑三氯金(III) 苯并噻唑-d4 苯并噻唑-7-乙酸 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基甲基-乙基-胺 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺